B. Riley Lowers Infinity Pharmaceuticals' Price Target to $3 from $5 to Reflect Delay in Eganelisib's Development, Uncertainty on Timing of Partnership; Maintains Buy Rating
B. Riley Lowers Infinity Pharmaceuticals' Price Target to $3 from $5 to Reflect Delay in Eganelisib's Development, Uncertainty on Timing of Partnership; Maintains Buy Rating
B. Riley将Infinity Pharmacticals的目标股价从5美元下调至3美元，以反映Eganelisib开发的延迟以及合作时机的不确定性；维持买入评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间